Truist Financial Maintains Editas Medicine(EDIT.US) With Buy Rating

储亿银行维持Editas Medicine(EDIT.US)买入评级

moomoo资讯 · 10/24 06:31 · 评级/大行评级

Truist Financial analyst Joon Lee maintains $Editas Medicine (EDIT.US)$ with a buy rating.

According to TipRanks data, the analyst has a success rate of 54.5% and a total average return of 29.0% over the past year.

AnalystRecentRatingAutoNews_211643_20241023_99b2cd7ef9fabcf3abdb272387ac0ba34ced4bcb_1729773080834237_mm_en

Furthermore, according to the comprehensive report, the opinions of $Editas Medicine (EDIT.US)$'s main analysts recently are as follows:

The firm believes that Editas Medicine's shift towards an in vivo SCD approach and the decision to partner out reni-cel may be a more strategic allocation of its expertise and resources, potentially leading to greater value creation, following the successful preclinical in vivo editing of HSPCs.
Editas Medicine has presented initial data from its in vivo approach, which involves the targeted lipid nanoparticle delivery to edit hematopoietic stem cells with the CRISPR-Cas12a enzyme. Alongside this, the company has expressed its intention to form global partnerships for reni-cel, prioritizing its resources on in vivo programs. Despite the promising early in vivo data, there is an expectation that investors may find it challenging to place significant value on a platform at such an initial stage of development.

Note:

TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.

Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.

TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.

储亿银行分析师Joon Lee维持$Editas Medicine (EDIT.US)$买入评级。

根据TipRanks数据显示，该分析师近一年总胜率为54.5%，总平均回报率为29.0%。

AnalystRecentRatingAutoNews_211643_20241023_99b2cd7ef9fabcf3abdb272387ac0ba34ced4bcb_1729773080834237_mm_sc

此外，综合报道，$Editas Medicine (EDIT.US)$近期主要分析师观点如下：

该公司认为，继HSPC的临床前活体编辑成功之后，Editas Medicine向体内SCD方法的转变以及与reni-cel合作的决定可能是其专业知识和资源的更具战略性的配置，有可能带来更大的价值创造。
Editas Medicine已经提供了其体内方法的初步数据，该方法涉及靶向脂质纳米颗粒输送，使用CRISPR-Cas12a酶编辑造血干细胞。除此之外，该公司还表示打算与reni-cel建立全球合作伙伴关系，将其资源优先用于体内项目。尽管早期的活体数据令人鼓舞，但预计投资者可能会发现在开发的初始阶段对平台进行重大估值具有挑战性。

提示:

TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。

TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。

分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。

总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。更多信息

Truist Financial Maintains Editas Medicine(EDIT.US) With Buy Rating

Truist Financial Maintains Editas Medicine(EDIT.US) With Buy Rating

风险及免责提示

声明